

be accessible to the public in one place. Under this new requirement, agencies will continue their current practice of submitting printed, signed copies of mandated reports directly to Congress and committees and subcommittees. All resources related to congressionally mandated reports for Federal agencies can be found at <https://www.gpo.gov/congressionally-mandated-reports>. For questions, please use the Congressionally Mandated Reports submission portal: <https://ask.gpo.gov/s/CMR>. Click the drop down arrow next to Ask a Question, and then select Agency User or Congressional User.

**Hugh Nathaniel Halpern,**

*Director, U.S. Government Publishing Office.*

[FR Doc. 2023–22336 Filed 10–6–23; 8:45 am]

BILLING CODE 1520–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Healthcare Infection Control Practices Advisory Committee (HICPAC)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Healthcare Infection Control Practices Advisory Committee (HICPAC). This is a virtual meeting. The public is welcomed to listen to the meeting live via webcast on the World Wide Web. The webcast link can be found on the HICPAC website at [www.cdc.gov/hicpac/meeting.html](http://www.cdc.gov/hicpac/meeting.html). Time will be available for public comment.

**DATES:** The meeting will be held on November 2, 2023, 9 a.m. to 5 p.m., EDT, and November 3, 2023, 9 a.m. to 12 p.m., EDT.

**ADDRESSES:** The meeting will be webcast live via the World Wide Web. The webcast link can be found on the HICPAC website at [www.cdc.gov/hicpac/meeting.html](http://www.cdc.gov/hicpac/meeting.html).

**FOR FURTHER INFORMATION CONTACT:**

Sydney Byrd, M.P.A., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE, Mailstop H16–3, Atlanta, Georgia 30329, Telephone (404) 718–8039. Email: [hicpac@cdc.gov](mailto:hicpac@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Purpose:* The Committee is charged with providing advice and guidance to

the Director, Division of Healthcare Quality Promotion (DHQP), the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, and the Secretary, Health and Human Services, regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

**Matters to be Considered:** The agenda will include updates on CDC's activities for prevention of healthcare-associated infections. It will also include updates from the following HICPAC workgroups: the Isolation Precautions Guideline workgroup, the Dental Unit Waterline Guideline Workgroup, the Healthcare Personnel Guideline Workgroup, and the National Healthcare Safety Network (NHSN) Workgroup. The agenda also includes updates on CDC and DHQP activities. Agenda items are subject to change as priorities dictate.

#### Public Participation

**Oral Public Comment:** This meeting will include time for members of the public to make an oral comment. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the following procedures: All persons interested in making an oral public comment at the November 2–3, 2023 HICPAC meeting must submit a request between October 2, 2023 and October 22, 2023, at <https://www.cdc.gov/hicpac/meeting.html> no later than 11:59 p.m., EDT, October 22, 2023, according to the instructions provided on the HICPAC website. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a random draw to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email on October 30, 2023. To accommodate the significant interest in participation in the oral public comment session of HICPAC meetings, each speaker will be limited to three minutes, and each speaker may only speak once per meeting.

**Written Public Comment:** The public is welcome to submit written comments in advance of the meeting. The written public comment period will open November 1, 2023, and will close at 11:59 p.m., EDT on November 6, 2023.

Comments should be submitted in writing by email to the HICPAC inbox at [hicpac@cdc.gov](mailto:hicpac@cdc.gov). All requests must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one single-spaced typed page in length. Written comments received in advance of the meeting will be included in the official record of the meeting.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–22327 Filed 10–6–23; 8:45 am]

BILLING CODE 4163–18–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Submission for Office of Management and Budget Review; Generic for Administration for Children and Families Program Monitoring Activities (Office of Management and Budget #: 0970–0558)

**AGENCY:** Office of Planning, Research, and Evaluation, Administration for Children and Families, U.S. Department of Health and Human Services.

**ACTION:** Request for public comments.

**SUMMARY:** The Administration for Children and Families (ACF) intends to request from the Office of Management and Budget (OMB) an extension of approval for an umbrella generic clearance for information collections related to ACF program office monitoring activities. ACF programs promote the economic and social well-being of families, children, individuals, and communities. The Generic for ACF Program Monitoring Activities allows ACF program offices to collect standardized information from recipients that receive federal funds to ensure oversight, evaluation, support purposes, and stewardship of federal funds. There are no changes proposed to

the terms of the generic. Burden estimates have been updated.

**DATES:** *Comments due within 30 days of publication.* OMB must make a decision about the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under 30-day Review-Open for Public Comments” or by using the search function. You can also obtain copies of the proposed collection of information by emailing

[OPREinfocollection@acf.hhs.gov](mailto:OPREinfocollection@acf.hhs.gov). Identify all requests by the title of the information collection.

**SUPPLEMENTARY INFORMATION:**

*Description:* Program monitoring is a post-award process through which ACF assesses a recipient’s programmatic performance and business management performance. Monitoring activities are necessary to ensure timely action by ACF to support grantees and protect federal interests.

Program offices use information collected under this generic clearance to monitor funding recipient activities and to provide support or take appropriate action, as needed. The information gathered is or will be used primarily for internal purposes, but aggregate data may be included in public materials such as Reports to Congress or program office documents. Following standard OMB requirements, ACF will submit a request for each individual data

collection activity under this generic clearance. Each request will include the individual form(s) or instrument(s), a justification specific to the individual information collection, and any supplementary documents. OMB is requested to review requests within 10 days of submission.

*Respondents:* ACF funding recipients.

**Annual Burden Estimates**

This request will extend approval of currently approved monitoring forms. Currently approved forms and related burden can be found here: [https://www.reginfo.gov/public/do/PRAICList?ref\\_nbr=202307-0970-014](https://www.reginfo.gov/public/do/PRAICList?ref_nbr=202307-0970-014).

Burden estimates for the next three years have been updated to reflect trends in use over the past three years. These are based on averages and actual individual requests will vary based on program office need.

Instrument	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Avg. burden per response (in hours)	Total burden (in hours)
New Program Monitoring Forms .....	1600	2.5	12	48,000

Mary B. Jones,  
ACF/OPRE Certifying Officer.  
[FR Doc. 2023–22382 Filed 10–6–23; 8:45 am]  
BILLING CODE 4184–79–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2023–N–3636]

**Food and Drug Administration Information Technology Strategy; Request for Comments; Correction**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is correcting a notice entitled “Food and Drug Administration Information Technology Strategy; Request for Comments” that appeared in the **Federal Register** of September 19, 2023. The document announced the availability of an information technology (IT) strategic plan entitled the “FDA Information Technology Strategy” and a request for comment on this IT Strategy. The document was published with an incorrect set of fiscal

year information. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:** Casi Alexander, Office of Digital Transformation, Food and Drug Administration, FDA Library, 5630 Fishers Lane, Rm. 1087, Rockville, MD 20857, 240–402–5171, email: [Casi.Alexander@fda.hhs.gov](mailto:Casi.Alexander@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of September 19, 2023 (88 FR 64435), in FR Doc. 2023–20136, the following correction is made:

On page 64436, in the third column, in the second paragraph, “Fiscal Years 2024–2026” is corrected to read “Fiscal Years 2024–2027.”

Dated: October 4, 2023.

Lauren K. Roth,  
Associate Commissioner for Policy.  
[FR Doc. 2023–22388 Filed 10–6–23; 8:45 am]  
BILLING CODE 4164–01–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2023–N–4202]

**Revocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of Mpox; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the revocations of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Life Technologies Corp. (a part of Thermo Fisher Scientific Inc.), for the TaqPath Monkeypox/Orthopox Virus DNA Kit, and Becton, Dickinson and Co., for the VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System. FDA revoked these Authorizations under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by these Authorization holders. The revocations, which include an explanation of the reasons for each revocation, are reprinted in this document.

**DATES:** The Authorization for the Life Technologies Corp. (a part of Thermo